Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 15 of 116

  1. KT-US-473-0133

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  2. L-leucovorin

    United Therapeutics Europe Ltd

    Colorectal Cancer

    phase 3 small molecule completed

    1 trial

  3. LHRHa

    Janssen Cilag International NV

    Prostatic Neoplasms

    phase 3 small molecule active

    1 trial

  4. LI

    Teva Pharma GmbH

    Squamous Cell Carcinoma of the Oral Cavity

    phase 3 mab completed

    1 trial

  5. LIBTAYO 350 mg concentrate for solution for infusion.

    Partner Therapeutics Limited

    Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%

    phase 3 small molecule active

    1 trial

  6. LORLATINIB

    Pfizer Australia Pty Ltd

    Advanced ALK positive non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  7. LOXO-BTK-20019

    Wuhan Createrna Science and Technology Co., Ltd

    Mantle cell lymphoma

    phase 3 small molecule active

    1 trial

  8. LOXO-BTK-20020

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  9. LOXO-BTK-20022

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

    phase 3 small molecule active

    1 trial

  10. LOXO-BTK-20023

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  11. LOXO-BTK-20030

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  12. LV305

    Lxo Ireland Designated Activity Company

    Synovial Sarcoma

    phase 3 mab terminated

    1 trial

  13. Lapatinib

    Novartis Pharmaceuticals

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  14. Lapatinib

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule completed

    1 trial

  15. Lapatinib

    Novartis Pharmaceuticals

    Neoplasms, Breast

    phase 3 small molecule terminated

    2 trials

  16. Lenalidomide

    Celgene Europe Limited

    B-cell Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    1 trial

  17. Lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 3 small molecule terminated

    1 trial

  18. Lenvatinib

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Hepatocellular

    phase 3 small molecule completed

    1 trial

  19. Lerotinib

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Esophageal Cancer

    phase 3 small molecule active

    1 trial

  20. Leuprorelin

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  21. Leuprorelin SR

    Takeda

    Prostatic Neoplasms, Locally Advanced

    phase 3 small molecule completed

    1 trial

  22. Levotiroxina Teva 25 microgrammi compresse

    Fondazione Telethon ETS

    Hodgkin and non Hodgkin lymphoma, Medulloblastoma

    phase 3 small molecule active

    1 trial

  23. Lifileucel plus Pembrolizumab

    Iovance Biotherapeutics B.V.

    Metastatic Melanoma

    phase 3 mab active

    1 trial

  24. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed Diffuse Large B-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  25. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

  26. Lynparza film-coated tablets for Recurrent ovarian cancer

    Fondazione Telethon ETS

    Recurrent ovarian cancer

    phase 3 small molecule active

    1 trial

  27. M15-656

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  28. M16-043

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  29. M19-708

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia in First Remission

    phase 3 small molecule active

    1 trial

  30. M20-621

    AbbVie Deutschland GmbH & Co. KG

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  31. M20-638

    AbbVie Deutschland GmbH & Co. KG

    Relapsed and Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  32. M22-003

    AbbVie Deutschland GmbH & Co. KG

    Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  33. M22-128

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  34. M23-721

    AbbVie Deutschland GmbH & Co. KG

    Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  35. M24-052

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  36. M24-064

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  37. M24-287

    AbbVie Deutschland GmbH & Co. KG

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  38. M25-287

    AbbVie Deutschland GmbH & Co. KG

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  39. M25-713

    AbbVie Deutschland GmbH & Co. KG

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  40. MB-108

    Moleculin Biotech

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  41. MB11-C-01-25

    Mabxience Research SL

    Previously Untreated Advanced (Unresectable or Metastatic) Melanoma

    phase 3 small molecule active

    1 trial

  42. MB12-C-02-24

    Mabxience Research SL

    advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  43. MEDI4736

    AstraZeneca

    Squamous Cell Carcinoma of the Head and Neck

    phase 3 mab completed

    1 trial

  44. MEDI4736

    AstraZeneca

    Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  45. MEDI4736 (Durvalumab)

    AstraZeneca

    Non-Small-Cell Lung Carcinoma NSCLC

    phase 3 mab active

    1 trial

  46. MEDI4736 Placebo, DURVALUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients

    phase 3 small molecule active

    1 trial

  47. MEDOPP545

    Stemline Therapeutics B.V.

    patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.

    phase 3 small molecule active

    1 trial

  48. MEP

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.